CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: UBA2 (ImmuneEditome ID:10054)

1. Gene summary of enriched editing regions for UBA2

check button Gene summary
Gene informationGene symbol

UBA2

Gene ID

10054

GeneSynonymsACCES|ARX|HRIHFB2115|SAE2
GeneCytomap

19q13.11

GeneTypeprotein-coding
GeneDescriptionSUMO-activating enzyme subunit 2|SUMO-1 activating enzyme subunit 2|SUMO1 activating enzyme subunit 2|UBA2, ubiquitin-activating enzyme E1 homolog|anthracycline-associated resistance ARX|ubiquitin-like 1-activating enzyme E1B
GeneModificationdate20230409
UniprotIDQ9UBT2;U3KQ55;U3KQ93;K7ES38;K7EPL2
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:34434181-34434400:+ENST00000592672.2ENSG00000126261.11UBA2ncRNA_intronicAluJrchr19:34434181-34434400:+.alignment
chr19:34438950-34442660:+ENST00000246548.7ENSG00000126261.11UBA2intronicAluY,AluSq,AluSx1,AluSz6,AluJb,L1M5chr19:34438950-34442660:+.alignment
chr19:34438950-34442660:+ENST00000439527.5ENSG00000126261.11UBA2intronicAluY,AluSq,AluSx1,AluSz6,AluJb,L1M5chr19:34438950-34442660:+.alignment
chr19:34438950-34442660:+ENST00000586313.1ENSG00000126261.11UBA2intronicAluY,AluSq,AluSx1,AluSz6,AluJb,L1M5chr19:34438950-34442660:+.alignment
chr19:34438950-34442660:+ENST00000590048.5ENSG00000126261.11UBA2intronicAluY,AluSq,AluSx1,AluSz6,AluJb,L1M5chr19:34438950-34442660:+.alignment
chr19:34444214-34444776:+ENST00000246548.7ENSG00000126261.11UBA2intronicMIRb,AluJr,AluSq2chr19:34444214-34444776:+.alignment
chr19:34444214-34444776:+ENST00000439527.5ENSG00000126261.11UBA2intronicMIRb,AluJr,AluSq2chr19:34444214-34444776:+.alignment
chr19:34444214-34444776:+ENST00000586313.1ENSG00000126261.11UBA2intronicMIRb,AluJr,AluSq2chr19:34444214-34444776:+.alignment
chr19:34444214-34444776:+ENST00000590048.5ENSG00000126261.11UBA2intronicMIRb,AluJr,AluSq2chr19:34444214-34444776:+.alignment
chr19:34455736-34457360:+ENST00000246548.7ENSG00000126261.11UBA2intronic(AT)n,AluSx,FLAM_C,AluSz,HAL1ME,AluSpchr19:34455736-34457360:+.alignment
chr19:34455736-34457360:+ENST00000439527.5ENSG00000126261.11UBA2intronic(AT)n,AluSx,FLAM_C,AluSz,HAL1ME,AluSpchr19:34455736-34457360:+.alignment
chr19:34455736-34457360:+ENST00000586313.1ENSG00000126261.11UBA2intronic(AT)n,AluSx,FLAM_C,AluSz,HAL1ME,AluSpchr19:34455736-34457360:+.alignment
chr19:34455736-34457360:+ENST00000591016.1ENSG00000126261.11UBA2intronic(AT)n,AluSx,FLAM_C,AluSz,HAL1ME,AluSpchr19:34455736-34457360:+.alignment
chr19:34469951-34470833:+ENST00000246548.7ENSG00000126261.11UBA2UTR3AluSq2,FLAM_A,AluSx3chr19:34469951-34470833:+.alignment


Top

2. Tumor-specific enriched editing regions for UBA2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr19:34469951-34470833:+BRCAEER3.7879e-04image
ENSG00000126261.11,UBA2BRCAEAG6.7414e-04image
chr19:34469951-34470833:+LUSCEER2.3023e-03image
ENSG00000126261.11,UBA2LUSCEAG2.3922e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr19:34469951-34470833:+CHOLPathEER3.2747e-023.0876e-020.4413image
ENSG00000126261.11,UBA2CHOLPathEAG3.2747e-023.0876e-020.4413image
ENSG00000126261.11,UBA2ESCAPathEAG3.7585e-021.8815e-020.2178image
chr19:34469951-34470833:+KIRPPathEER4.2082e-024.3069e-030.2568image
ENSG00000126261.11,UBA2KIRPPathEAG4.2082e-024.3069e-030.2568image
ENSG00000126261.11,UBA2THCAPathEAG1.6882e-037.5860e-040.1677image
chr19:34469951-34470833:+THCAPathEER1.6882e-037.5860e-040.1677image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for UBA2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:34469951-34470833:+DLBCEERENSG00000235314,LINC00957-0.57973.7734e-022.8892e-03-0.4388imageNNNAMacrophages_M1GSVA_HALLMARK_PANCREAS_BETA_CELLS
chr19:34469951-34470833:+DLBCEERENSG00000101746,NOL4-0.55264.4441e-023.9754e-03-0.4256imageNNNAB_cells_naive
chr19:34469951-34470833:+UVMEERENSG00000101843,PSMD10-0.64232.8578e-052.0882e-07-0.5636imageNNPSMD10T_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION
chr19:34469951-34470833:+UVMEERENSG00000146729,GBAS-0.62344.4193e-051.3053e-07-0.5713imageNNNAT_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION
chr19:34469951-34470833:+UVMEERENSG00000173674,EIF1AX-0.60375.8526e-058.0683e-07-0.5403imageNNNAT_cells_follicular_helperGSVA_HALLMARK_KRAS_SIGNALING_DN
chr19:34469951-34470833:+UVMEERENSG00000105176,URI1-0.60457.7829e-051.3465e-07-0.5708imageNNNAT_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION
chr19:34469951-34470833:+UVMEERENSG00000065613,SLK-0.60487.7882e-055.4808e-07-0.5471imageNNSLKT_cells_follicular_helperGSVA_HALLMARK_KRAS_SIGNALING_DN
chr19:34469951-34470833:+UVMEERENSG00000059588,TARBP1-0.57791.5675e-048.1586e-06-0.4959imageNNTARBP1T_cells_regulatory_(Tregs)GSVA_HALLMARK_KRAS_SIGNALING_DN
chr19:34469951-34470833:+UVMEERENSG00000182903,ZNF721-0.58161.5927e-047.2000e-06-0.4984imageNNNAT_cells_follicular_helperGSVA_HALLMARK_KRAS_SIGNALING_DN
chr19:34469951-34470833:+UVMEERENSG00000164022,AIMP1-0.57731.6037e-043.1132e-07-0.5569imageNNAIMP1T_cells_follicular_helperGSVA_HALLMARK_KRAS_SIGNALING_DN

More results



Top

4. Enriched editing regions and immune related splicing for UBA2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000126261.11,UBA2
ESCAEAGA3ENSG00000163539.11chr333644756:33644903:33632291:33632371:33632291:33632374-0.41218.5202e-032.5368e-06-0.4210imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184NAGSVA_HALLMARK_APICAL_SURFACE
ENSG00000126261.11,UBA2
ESCAEAGIRENSG00000008294.16chr1750974770:50974947:50975862:50975901-0.37434.1654e-023.1013e-06-0.4064imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184NAMast_cells_restingGSVA_HALLMARK_MYOGENESIS
ENSG00000126261.11,UBA2
KICHEAGMEXENSG00000129657.10chr1777215766:77215779:77215818:77216114:77216231:77216322:77216348:77216387-0.44673.7901e-028.5334e-05-0.5572imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM6;RC3H1;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAB_cells_memoryGSVA_HALLMARK_E2F_TARGETS
ENSG00000126261.11,UBA2
KICHEAGMEXENSG00000129657.10chr1777215766:77215779:77215818:77216114:77216244:77216322:77216348:77216387-0.44673.7901e-028.5334e-05-0.5572imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM6;RC3H1;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAB_cells_memoryGSVA_HALLMARK_E2F_TARGETS
ENSG00000126261.11,UBA2
KICHEAGMEXENSG00000129657.10chr1777215766:77215779:77215818:77216114:77216296:77216322:77216348:77216387-0.44673.7901e-028.5334e-05-0.5572imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM6;RC3H1;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAB_cells_memoryGSVA_HALLMARK_E2F_TARGETS
ENSG00000126261.11,UBA2
KICHEAGMEXENSG00000129657.10chr1777215766:77215779:77215818:77216127:77216205:77216322:77216348:77216387-0.44673.7901e-028.5334e-05-0.5572imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM6;RC3H1;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAB_cells_memoryGSVA_HALLMARK_E2F_TARGETS
ENSG00000126261.11,UBA2
KICHEAGMEXENSG00000129657.10chr1777215766:77215779:77215818:77216127:77216231:77216322:77216348:77216387-0.44673.7901e-028.5334e-05-0.5572imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM6;RC3H1;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAB_cells_memoryGSVA_HALLMARK_E2F_TARGETS
ENSG00000126261.11,UBA2
KICHEAGMEXENSG00000129657.10chr1777215766:77215779:77215818:77216153:77216153:77216322:77216348:77216387-0.44673.7901e-028.3213e-05-0.5579imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM6;RC3H1;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAB_cells_memoryGSVA_HALLMARK_E2F_TARGETS
ENSG00000126261.11,UBA2
KICHEAGMEXENSG00000129657.10chr1777215766:77215779:77215818:77216153:77216166:77216322:77216348:77216387-0.44673.7901e-028.3213e-05-0.5579imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM6;RC3H1;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAB_cells_memoryGSVA_HALLMARK_E2F_TARGETS
ENSG00000126261.11,UBA2
KICHEAGMEXENSG00000129657.10chr1777215766:77215779:77215818:77216153:77216231:77216322:77216348:77216387-0.44673.7901e-028.3213e-05-0.5579imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM6;RC3H1;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAB_cells_memoryGSVA_HALLMARK_E2F_TARGETS

More results



Top

5. Enriched editing regions and immune infiltration for UBA2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:34469951-34470833:+ACCEERDendritic_cells_activated1.5016e-020.3356image
ENSG00000126261.11,UBA2ACCEAGDendritic_cells_activated1.5016e-020.3356image
chr19:34469951-34470833:+BLCAEERMacrophages_M22.1928e-030.1653image
ENSG00000126261.11,UBA2BLCAEAGMacrophages_M27.3403e-030.1445image
chr19:34469951-34470833:+BRCAEERT_cells_regulatory_(Tregs)2.0258e-020.0805image
ENSG00000126261.11,UBA2BRCAEAGT_cells_regulatory_(Tregs)4.7834e-030.0971image
chr19:34469951-34470833:+CESCEERDendritic_cells_resting2.6347e-020.1428image
ENSG00000126261.11,UBA2CESCEAGDendritic_cells_resting2.6347e-020.1428image
chr19:34469951-34470833:+CHOLEERB_cells_memory1.4611e-020.4920image
ENSG00000126261.11,UBA2CHOLEAGB_cells_memory1.4611e-020.4920image
chr19:34469951-34470833:+COADEERDendritic_cells_resting1.8348e-03-0.2359image
ENSG00000126261.11,UBA2COADEAGDendritic_cells_resting2.2890e-03-0.2278image
chr19:34469951-34470833:+DLBCEERMast_cells_activated2.8515e-020.3303image
ENSG00000126261.11,UBA2DLBCEAGMast_cells_activated2.8515e-020.3303image
chr19:34438950-34442660:+ESCAEERB_cells_naive3.4246e-020.2247image
chr19:34469951-34470833:+ESCAEERMacrophages_M01.9799e-020.2363image
ENSG00000126261.11,UBA2ESCAEAGT_cells_CD4_naive3.1403e-020.1926image
chr19:34469951-34470833:+GBMEERT_cells_gamma_delta4.1157e-020.1959image
ENSG00000126261.11,UBA2GBMEAGT_cells_gamma_delta4.1157e-020.1959image
chr19:34469951-34470833:+HNSCEERMacrophages_M13.9951e-060.2433image
ENSG00000126261.11,UBA2HNSCEAGMacrophages_M13.9951e-060.2433image
chr19:34469951-34470833:+KIRCEERMacrophages_M04.4230e-020.1193image
ENSG00000126261.11,UBA2KIRCEAGMacrophages_M04.3056e-020.1195image
chr19:34469951-34470833:+KIRPEERMast_cells_resting2.6866e-020.1905image
ENSG00000126261.11,UBA2KIRPEAGMast_cells_resting2.6866e-020.1905image
chr19:34469951-34470833:+LGGEERT_cells_CD4_memory_resting2.1534e-02-0.1876image
ENSG00000126261.11,UBA2LGGEAGT_cells_CD4_memory_resting3.6484e-02-0.1704image
chr19:34469951-34470833:+LUADEERMacrophages_M11.1996e-02-0.1516image
ENSG00000126261.11,UBA2LUADEAGMacrophages_M11.3456e-02-0.1481image
chr19:34469951-34470833:+MESOEERT_cells_follicular_helper2.0283e-020.3123image
ENSG00000126261.11,UBA2MESOEAGT_cells_follicular_helper2.0283e-020.3123image
chr19:34438950-34442660:+OVEERT_cells_CD83.3866e-030.2993image
chr19:34469951-34470833:+OVEERMacrophages_M14.0593e-020.1401image
ENSG00000126261.11,UBA2OVEAGB_cells_naive4.9407e-02-0.1320image
chr19:34469951-34470833:+PAADEERDendritic_cells_activated2.3268e-050.4115image
ENSG00000126261.11,UBA2PAADEAGDendritic_cells_activated2.3268e-050.4115image
chr19:34469951-34470833:+PCPGEERB_cells_naive1.5504e-020.1967image
ENSG00000126261.11,UBA2PCPGEAGB_cells_naive1.5504e-020.1967image
chr19:34469951-34470833:+PRADEERMast_cells_activated1.8403e-03-0.1566image
ENSG00000126261.11,UBA2PRADEAGMast_cells_activated1.6432e-03-0.1579image
chr19:34469951-34470833:+READEERDendritic_cells_resting8.9604e-03-0.3124image
ENSG00000126261.11,UBA2READEAGDendritic_cells_resting8.9604e-03-0.3124image
chr19:34469951-34470833:+SARCEERDendritic_cells_activated8.8354e-03-0.1871image
ENSG00000126261.11,UBA2SARCEAGDendritic_cells_activated9.9411e-03-0.1842image
chr19:34469951-34470833:+SKCMEERT_cells_CD81.0697e-090.2926image
ENSG00000126261.11,UBA2SKCMEAGT_cells_CD81.1074e-090.2924image
chr19:34438950-34442660:+STADEERMacrophages_M03.5770e-02-0.1880image
chr19:34469951-34470833:+STADEERB_cells_naive1.8359e-02-0.2027image
ENSG00000126261.11,UBA2STADEAGMonocytes2.6000e-020.1615image
chr19:34469951-34470833:+TGCTEERDendritic_cells_resting3.0473e-02-0.1810image
ENSG00000126261.11,UBA2TGCTEAGDendritic_cells_resting3.0473e-02-0.1810image
chr19:34469951-34470833:+THCAEERB_cells_memory7.9540e-030.1322image
ENSG00000126261.11,UBA2THCAEAGB_cells_memory7.9540e-030.1322image
chr19:34469951-34470833:+THYMEERMast_cells_resting5.7168e-050.3789image
ENSG00000126261.11,UBA2THYMEAGMast_cells_resting5.0619e-050.3797image
chr19:34469951-34470833:+UCECEERT_cells_regulatory_(Tregs)3.6495e-030.2634image
ENSG00000126261.11,UBA2UCECEAGT_cells_regulatory_(Tregs)6.6761e-030.2434image
chr19:34469951-34470833:+UCSEERB_cells_naive1.1985e-02-0.3396image
ENSG00000126261.11,UBA2UCSEAGB_cells_naive1.1985e-02-0.3396image
chr19:34469951-34470833:+UVMEERT_cells_regulatory_(Tregs)1.1820e-020.2932image
ENSG00000126261.11,UBA2UVMEAGT_cells_regulatory_(Tregs)1.1940e-020.2928image


Top

6. Enriched editing regions and immune gene sets for UBA2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000126261.11,UBA2STADEAG1.5882e-030.22762.3804e-020.16405.6185e-030.20021.7884e-050.3058image
chr19:34469951-34470833:+STADEER5.7290e-040.29261.0956e-020.21837.2116e-040.28751.4133e-050.3641image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr19:34469951-34470833:+BLCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.5727e-030.1705image
ENSG00000126261.11,UBA2BLCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.1623e-030.1747image
ENSG00000126261.11,UBA2BRCAGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG2.8408e-100.2150image
chr19:34469951-34470833:+BRCAGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER4.3703e-080.1885image
chr19:34469951-34470833:+CESCGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.9516e-030.1903image
ENSG00000126261.11,UBA2CESCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.9516e-030.1903image
ENSG00000126261.11,UBA2CHOLGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.6723e-02-0.4516image
chr19:34469951-34470833:+CHOLGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.6723e-02-0.4516image
chr19:34469951-34470833:+ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.8911e-020.2101image
ENSG00000126261.11,UBA2ESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG2.1393e-030.2721image
chr19:34438950-34442660:+ESCAGSVA_HALLMARK_KRAS_SIGNALING_DNEER9.3433e-030.2741image
chr19:34469951-34470833:+GBMGSVA_HALLMARK_G2M_CHECKPOINTEER1.0196e-02-0.2451image
ENSG00000126261.11,UBA2GBMGSVA_HALLMARK_G2M_CHECKPOINTEAG1.0196e-02-0.2451image
ENSG00000126261.11,UBA2HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.1875e-060.2457image
chr19:34469951-34470833:+HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.1875e-060.2457image
ENSG00000126261.11,UBA2KICHGSVA_HALLMARK_MITOTIC_SPINDLEEAG4.1236e-02-0.2666image
chr19:34469951-34470833:+KICHGSVA_HALLMARK_MITOTIC_SPINDLEEER4.1236e-02-0.2666image
ENSG00000126261.11,UBA2KIRCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.1886e-020.1483image
chr19:34469951-34470833:+KIRCGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.1732e-020.1491image
ENSG00000126261.11,UBA2LAMLGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.5581e-020.3619image
ENSG00000126261.11,UBA2LGGGSVA_HALLMARK_MYOGENESISEAG3.4702e-030.2364image
chr19:34469951-34470833:+LGGGSVA_HALLMARK_MITOTIC_SPINDLEEER4.1558e-03-0.2327image
chr19:34469951-34470833:+LIHCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.1538e-03-0.2820image
ENSG00000126261.11,UBA2LIHCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.1538e-03-0.2820image
ENSG00000126261.11,UBA2LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.4281e-030.1417image
chr19:34469951-34470833:+LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.1480e-030.1393image
chr19:34469951-34470833:+MESOGSVA_HALLMARK_G2M_CHECKPOINTEER1.5744e-02-0.3242image
ENSG00000126261.11,UBA2MESOGSVA_HALLMARK_G2M_CHECKPOINTEAG1.5744e-02-0.3242image
chr19:34438950-34442660:+OVGSVA_HALLMARK_PEROXISOMEEER6.7732e-040.3444image
ENSG00000126261.11,UBA2OVGSVA_HALLMARK_ADIPOGENESISEAG6.4057e-060.2977image
chr19:34469951-34470833:+OVGSVA_HALLMARK_ADIPOGENESISEER6.0194e-050.2707image
ENSG00000126261.11,UBA2PAADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.7857e-02-0.2377image
chr19:34469951-34470833:+PAADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER1.7857e-02-0.2377image
ENSG00000126261.11,UBA2PCPGGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.1760e-02-0.2045image
chr19:34469951-34470833:+PCPGGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.1760e-02-0.2045image
ENSG00000126261.11,UBA2PRADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.9681e-020.1094image
chr19:34469951-34470833:+PRADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.2666e-020.1078image
chr19:34469951-34470833:+SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.7291e-070.2483image
ENSG00000126261.11,UBA2SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.8722e-070.2478image
chr19:34469951-34470833:+STADGSVA_HALLMARK_HYPOXIAEER1.4133e-050.3641image
ENSG00000126261.11,UBA2STADGSVA_HALLMARK_ADIPOGENESISEAG1.3193e-060.3425image
chr19:34438950-34442660:+STADGSVA_HALLMARK_PANCREAS_BETA_CELLSEER4.2696e-020.1816image
ENSG00000126261.11,UBA2TGCTGSVA_HALLMARK_KRAS_SIGNALING_UPEAG4.1963e-030.2381image
chr19:34469951-34470833:+TGCTGSVA_HALLMARK_KRAS_SIGNALING_UPEER4.1963e-030.2381image
ENSG00000126261.11,UBA2THCAGSVA_HALLMARK_DNA_REPAIREAG9.4230e-030.1294image
chr19:34469951-34470833:+THCAGSVA_HALLMARK_DNA_REPAIREER9.4230e-030.1294image
ENSG00000126261.11,UBA2THYMGSVA_HALLMARK_G2M_CHECKPOINTEAG7.4287e-07-0.4552image
chr19:34469951-34470833:+THYMGSVA_HALLMARK_G2M_CHECKPOINTEER1.6065e-06-0.4446image
ENSG00000126261.11,UBA2UCECGSVA_HALLMARK_COAGULATIONEAG1.6536e-030.2808image
chr19:34469951-34470833:+UCECGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER2.1543e-030.2775image
ENSG00000126261.11,UBA2UCSGSVA_HALLMARK_APOPTOSISEAG7.2667e-040.4459image
chr19:34469951-34470833:+UCSGSVA_HALLMARK_APOPTOSISEER7.2667e-040.4459image
ENSG00000126261.11,UBA2UVMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.6103e-050.4815image
chr19:34469951-34470833:+UVMGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.5643e-050.4822image


Top

7. Enriched editing regions and drugs for UBA2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr19:34469951-34470833:+ACCABT.263EER6.3623e-030.3736image
ENSG00000126261.11,UBA2ACCABT.263EAG6.3623e-030.3736image
ENSG00000126261.11,UBA2BLCAEHT.1864EAG1.8686e-040.2004image
chr19:34469951-34470833:+BLCAEHT.1864EER2.0632e-040.1997image
ENSG00000126261.11,UBA2BRCAGNF.2EAG1.7627e-05-0.1473image
chr19:34469951-34470833:+BRCAGNF.2EER1.8323e-04-0.1294image
chr19:34469951-34470833:+CESCLapatinibEER1.2046e-04-0.2462image
ENSG00000126261.11,UBA2CESCLapatinibEAG1.2046e-04-0.2462image
ENSG00000126261.11,UBA2CHOLFTI.277EAG4.2740e-03-0.5618image
chr19:34469951-34470833:+CHOLFTI.277EER4.2740e-03-0.5618image
chr19:34469951-34470833:+COADCytarabineEER2.3861e-02-0.1722image
ENSG00000126261.11,UBA2COADCytarabineEAG2.5943e-02-0.1674image
chr19:34438950-34442660:+ESCAGNF.2EER3.8262e-02-0.2200image
ENSG00000126261.11,UBA2ESCAABT.888EAG3.9359e-030.2561image
chr19:34469951-34470833:+ESCAFH535EER4.0164e-030.2896image
ENSG00000126261.11,UBA2GBMErlotinibEAG9.3146e-03-0.2480image
chr19:34469951-34470833:+GBMErlotinibEER9.3146e-03-0.2480image
ENSG00000126261.11,UBA2HNSCCGP.60474EAG2.2660e-04-0.1956image
chr19:34469951-34470833:+HNSCCGP.60474EER2.2660e-04-0.1956image
ENSG00000126261.11,UBA2KIRCGSK269962AEAG8.3124e-03-0.1555image
chr19:34469951-34470833:+KIRCGSK269962AEER2.4562e-03-0.1787image
chr19:34469951-34470833:+KIRPAKT.inhibitor.VIIIEER1.8691e-020.2022image
ENSG00000126261.11,UBA2KIRPAKT.inhibitor.VIIIEAG1.8691e-020.2022image
ENSG00000126261.11,UBA2LGGGNF.2EAG1.8339e-03-0.2516image
chr19:34469951-34470833:+LGGGNF.2EER2.6100e-03-0.2441image
chr19:34469951-34470833:+LIHCFTI.277EER2.2306e-02-0.2003image
ENSG00000126261.11,UBA2LIHCFTI.277EAG2.2306e-02-0.2003image
ENSG00000126261.11,UBA2LUSCCI.1040EAG5.0337e-03-0.1396image
chr19:34469951-34470833:+LUSCCI.1040EER5.2574e-03-0.1390image
chr19:34469951-34470833:+MESOEpothilone.BEER6.9015e-030.3602image
ENSG00000126261.11,UBA2MESOEpothilone.BEAG6.9015e-030.3602image
ENSG00000126261.11,UBA2OVABT.263EAG8.2625e-030.1769image
chr19:34438950-34442660:+OVMetforminEER9.9914e-03-0.2645image
chr19:34469951-34470833:+OVAS601245EER5.9474e-03-0.1875image
ENSG00000126261.11,UBA2PAADIPA.3EAG3.0653e-020.2219image
chr19:34469951-34470833:+PAADIPA.3EER3.0653e-020.2219image
ENSG00000126261.11,UBA2PCPGATRAEAG6.6875e-030.2198image
chr19:34469951-34470833:+PCPGATRAEER6.6875e-030.2198image
ENSG00000126261.11,UBA2PRADBortezomibEAG2.0021e-02-0.1170image
chr19:34469951-34470833:+PRADBortezomibEER1.8779e-02-0.1185image
ENSG00000126261.11,UBA2READJNK.9LEAG7.2739e-030.3204image
chr19:34469951-34470833:+READJNK.9LEER7.2739e-030.3204image
chr19:34469951-34470833:+SARCAICAREER2.8206e-02-0.1572image
ENSG00000126261.11,UBA2SARCAICAREAG2.8625e-02-0.1568image
ENSG00000126261.11,UBA2SKCMCGP.60474EAG6.3021e-07-0.2408image
chr19:34469951-34470833:+SKCMCGP.60474EER5.8999e-07-0.2414image
ENSG00000126261.11,UBA2STADGW843682XEAG1.9239e-05-0.3046image
chr19:34469951-34470833:+STADGW843682XEER6.7561e-05-0.3360image
chr19:34438950-34442660:+STADBMS.708163EER1.4778e-03-0.2814image
ENSG00000126261.11,UBA2TGCTElesclomolEAG4.3141e-030.2374image
chr19:34469951-34470833:+TGCTElesclomolEER4.3141e-030.2374image
chr19:34469951-34470833:+THCAJNJ.26854165EER1.0732e-020.1271image
ENSG00000126261.11,UBA2THCAJNJ.26854165EAG1.0732e-020.1271image
chr19:34469951-34470833:+THYMGW.441756EER1.1098e-07-0.4861image
ENSG00000126261.11,UBA2THYMATRAEAG1.2041e-070.4829image
ENSG00000126261.11,UBA2UCECLFM.A13EAG2.6318e-03-0.2689image
chr19:34469951-34470833:+UCECLFM.A13EER5.5624e-03-0.2516image
ENSG00000126261.11,UBA2UCSBortezomibEAG3.5358e-04-0.4685image
chr19:34469951-34470833:+UCSBortezomibEER3.5358e-04-0.4685image
chr19:34469951-34470833:+UVMBexaroteneEER5.8287e-05-0.4525image
ENSG00000126261.11,UBA2UVMBexaroteneEAG5.9161e-05-0.4522image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType